NCT05222308 is a NA clinical trial of Post-Mortem Plan in Terminal Cancer, sponsored by University of Colorado, Denver.

Who is sponsoring NCT05222308?

NCT05222308 is sponsored by University of Colorado, Denver.

What drugs are being tested in NCT05222308?

Interventions in NCT05222308: Post-Mortem Plan.

What condition does NCT05222308 study?

NCT05222308 studies Terminal Cancer, Metastatic Cancer.

Is NCT05222308 still recruiting?

NCT05222308 is currently withdrawn. Last updated 8 July 2025.

Last reviewed 2025-07-08 · How we verify

NCT05222308

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced Planning for Online Accounts and Data

Withdrawn NA Last updated 8 July 2025

What this trial tests

NA trial testing Post-Mortem Plan in Terminal Cancer. Withdrawn.

Timeline

17 September 2021

Primary endpoint
27 September 2024

27 September 2024

Quick facts

Lead sponsor	University of Colorado, Denver
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Start date	17 September 2021
Primary completion	27 September 2024
Estimated completion	27 September 2024

Drugs / interventions tested

Post-Mortem Plan

Conditions studied

Terminal Cancer — all drugs for Terminal Cancer →
Metastatic Cancer — all drugs for Metastatic Cancer →

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 100, any sex, with Terminal Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed research consists of engagements with terminal cancer patients and their friends and family as they engage in end-of-life planning.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Terminal Cancer

Currently open trials in the same condition.

NCT06018896 — Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer · Phase 2 · recruiting

Other University of Colorado, Denver trials

Trials by the same sponsor.

NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05222308 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 8 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing